Department of Omics Medicine

Department of Omics Medicine was established on April 1, 2019 as Departments of Industry-Academia Collaboration with Shimadzu Corporation.

If cancer can be detected at the earliest possible stage, it may be possible to treat the cancer radically, which is expected to lead to a reduction in the cancer mortality rate and an improvement in patients' quality of life (QOL). Therefore, the purpose of this course is to develop a system for the early detection of major types of cancer, such as colorectal cancer and breast cancer, and then to put it into practical use and conduct verification with the aim of implementing it in society.

The research and development in this course employs a new analytical technology called "metabolomics." "Metabolomics" is a technology that uses an analytical instrument called a mass spectrometer to simultaneously analyze various metabolites present in the body, and by using this technology to perform analysis, it is possible to obtain a more detailed picture of metabolic changes in the body.

We are working on research and development based on the concept that "Could metabolic abnormalities in the body be involved in the onset of cancer?" and "Could detecting metabolic abnormalities lead to the development of a system that can detect cancer at the earliest possible stage?" We hope to contribute to the medical and health fields in society by utilizing the research and development capabilities of both our university and Shimadzu Corporation and by advancing research and development through a close industry-academia collaboration system.